The non-profit organization Discovery Consortium has been established in Japan to try and lift the diagnosis rate for HAE up to the kind of levels seen in North America and Europe. At the moment we estimate that only 20 % of all Japanese patients have been diagnosed.
The majority of the funding for the project is coming from the pharmaceutical companies, with equal funding from Takeda, CSL, and Torii who represent BioCryst in Japan. I am on the Board of Directors along with the leading doctors in the field.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.